Alternatives to Hyrimoz If You Can't Fill Your Prescription

If your pharmacy can't fill Hyrimoz (adalimumab-adaz) in time, or if your insurance no longer covers it, you are not without options. There are multiple FDA-approved alternatives — both within the adalimumab biosimilar family and in other drug classes — that your doctor may consider. Here's what you need to know before your next appointment.

Important: Never stop taking Hyrimoz without talking to your doctor first. Abruptly discontinuing a TNF inhibitor can cause disease flares and, in some cases, make it harder to re-achieve remission when you restart.

Option 1: Interchangeable Adalimumab Biosimilars (Same Drug, Different Brand)

Because Hyrimoz is a biosimilar to Humira (adalimumab), the most straightforward alternatives are other FDA-approved adalimumab biosimilars. The FDA has designated several as interchangeable — meaning pharmacists may be able to substitute one for another without a new prescription in most states. Clinical data, including the NOR-SWITCH trial and subsequent real-world studies, supports the safety of switching between adalimumab products.

Here are the key interchangeable adalimumab biosimilars available in the U.S. in 2026:

Hadlima (adalimumab-bwwd) — Samsung Bioepis / Organon

Hadlima is a high-concentration, citrate-free adalimumab biosimilar with full interchangeable status. It's the preferred biosimilar under some PBM formularies and is often available through specialty pharmacies that also carry Hyrimoz. Hadlima covers all the same indications as Hyrimoz. The unbranded version is available at a list price similar to unbranded Hyrimoz (roughly $1,300–$1,900/month).

Cyltezo (adalimumab-adbm) — Boehringer Ingelheim

Cyltezo was the first adalimumab biosimilar to receive interchangeable designation from the FDA in 2021. It's available in citrate-free formulations and covers all Humira indications. Express Scripts (via its Quallent private-label program) prefers Cyltezo, so patients with Express Scripts coverage may find it easier to access than Hyrimoz.

Amjevita (adalimumab-atto) — Amgen

Amjevita was the first Humira biosimilar approved by the FDA (2016) and the first to launch in the U.S. (January 2023). It has interchangeable status and is available in both low- and high-concentration formulations. Amjevita is covered by many insurance plans and may be available in specialty pharmacies that stock a broader range of adalimumab products.

Other Interchangeable Biosimilars: Simlandi, Yuflyma, Hulio

Simlandi (adalimumab-ryvk, Alvotech/Teva), Yuflyma (adalimumab-aaty, Celltrion), and Hulio (adalimumab-fkjp, Biocon) also carry interchangeable status. Yuflyma is notable for being FDA-approved for use in children for hidradenitis suppurativa and uveitis — indications where not all biosimilars are approved for pediatric patients.

Option 2: Brand-Name Humira (adalimumab)

Humira (the reference product made by AbbVie) is still available, though it has a higher list price ($7,000–$11,000/month without insurance) and is increasingly being removed from preferred formulary status by major PBMs. AbbVie's co-pay assistance program can reduce monthly costs to as little as $5 for eligible commercially insured patients. Humira may be an option if biosimilars are unavailable or not well tolerated.

Option 3: Other Biologic Drug Classes (Different Mechanism)

If adalimumab products are not an option due to intolerance, lack of response, or persistent access issues, your doctor may consider biologics or targeted therapies from other drug classes. The right choice depends on your specific diagnosis:

Enbrel (etanercept): Another TNF inhibitor; approved for RA, PsA, AS, plaque psoriasis. Not approved for Crohn's or UC. Works differently from adalimumab (fusion protein vs. monoclonal antibody).

Remicade / infliximab biosimilars: IV-infused TNF inhibitor; approved for RA, PsA, AS, Crohn's, UC, plaque psoriasis. Requires infusion center visits every 6–8 weeks.

Rinvoq (upadacitinib): Oral JAK inhibitor approved for RA, PsA, AS, Crohn's, UC, and plaque psoriasis. A convenient pill option. Different safety profile from TNF inhibitors (black box warning for DVT, cancer, cardiovascular events in certain populations).

Skyrizi (risankizumab): IL-23 inhibitor approved for Crohn's, UC, PsA, and plaque psoriasis. Quarterly subcutaneous injections after induction.

Orencia (abatacept): Approved for RA and PsA. T-cell costimulation blocker. Available as IV infusion or subcutaneous injection.

How to Talk to Your Doctor About Switching

When you speak to your prescriber, it helps to come prepared. Ask these questions:

"Can I switch to another interchangeable biosimilar while I work out my Hyrimoz access issue?"

"Which alternative is preferred by my insurance right now?"

"Are there any clinical reasons I specifically need adalimumab rather than a different biologic?"

"What happens if I miss a dose or two while this gets sorted out?"

Bottom Line

If you can't fill Hyrimoz, the fastest path forward is usually switching to another interchangeable adalimumab biosimilar that your pharmacy stocks and your insurance covers. For why finding Hyrimoz is so difficult in the first place, read Why Is Hyrimoz So Hard to Find? And remember: any of the interchangeable biosimilars — Hadlima, Cyltezo, Amjevita, Simlandi, Yuflyma, or Hulio — is clinically equivalent to Hyrimoz and can be a safe short-term or long-term substitute with proper medical guidance.

Need help finding Hyrimoz or an alternative in stock? medfinder calls pharmacies near you to locate your medication.